Cargando…

Genome stability of the vaccine strain VACΔ6

Due to cessation of mass smallpox vaccination in 1980, the collective immunity of humans against orthopoxvirus infections has virtually been lost. Therefore, the risk of spreading zoonotic human orthopoxvirus infections caused by monkeypox and cowpox viruses has increased in the world. First-generat...

Descripción completa

Detalles Bibliográficos
Autores principales: Maksyutov, R.A., Yakubitskiy, S.N., Kolosova, I.V., Tregubchak, T.V., Shvalov, A.N., Gavrilova, E.V., Shchelkunov, S.N.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Federal Research Center Institute of Cytology and Genetics of Siberian Branch of the Russian Academy of Sciences 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9284249/
https://www.ncbi.nlm.nih.gov/pubmed/35903306
http://dx.doi.org/10.18699/VJGB-22-48
_version_ 1784747523974365184
author Maksyutov, R.A.
Yakubitskiy, S.N.
Kolosova, I.V.
Tregubchak, T.V.
Shvalov, A.N.
Gavrilova, E.V.
Shchelkunov, S.N.
author_facet Maksyutov, R.A.
Yakubitskiy, S.N.
Kolosova, I.V.
Tregubchak, T.V.
Shvalov, A.N.
Gavrilova, E.V.
Shchelkunov, S.N.
author_sort Maksyutov, R.A.
collection PubMed
description Due to cessation of mass smallpox vaccination in 1980, the collective immunity of humans against orthopoxvirus infections has virtually been lost. Therefore, the risk of spreading zoonotic human orthopoxvirus infections caused by monkeypox and cowpox viruses has increased in the world. First-generation smallpox vaccines based on Vaccinia virus (VAC) are reactogenic and therefore not suitable for mass vaccination under current conditions. This necessitates the development of modern safe live vaccines based on VAC using genetic engineering. We created the VACΔ6 strain by transient dominant selection. In the VACΔ6 genome, f ive virulence genes were intentionally deleted, and one gene was inactivated by inserting a synthetic DNA fragment. The virus was passaged 71 times in CV-1 cells to obtain the VACΔ6 strain from the VAC LIVP clonal variant. Such a long passage history might have led to additional off-target mutations in VACΔ6 compared to the original LIVP variant. To prevent this, we performed a genome-wide sequencing of VAC LIVP, VACΔ6, and f ive intermediate viral strains to assess possible off-target mutations. A comparative analysis of complete viral genomes showed that, in addition to target mutations, only two nucleotide substitutions occurred spontaneously when obtaining VACΔ4 from the VACΔ3 strain; the mutations persisting in the VACΔ5 and VACΔ6 genomes. Both nucleotide substitutions are located in intergenic regions (positions 1431 and 189738 relative to LIVP), which indicates an extremely rare occurrence of off-target mutations when using transient dominant selection to obtain recombinant VAC variants with multiple insertions/deletions. To assess the genome stability of the resulting attenuated vaccine strain, 15 consecutive cycles of cultivation of the industrial VACΔ6 strain were performed in 4647 cells certif ied for vaccine production in accordance with the “Guidelines for Clinical Trials of Medicinal Products”. PCR and sequencing analysis of six DNA fragments corresponding to the regions of disrupted genes in VACΔ6 showed that all viral DNA sequences remained unchanged after 15 passages in 4647 cells.
format Online
Article
Text
id pubmed-9284249
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher The Federal Research Center Institute of Cytology and Genetics of Siberian Branch of the Russian Academy of Sciences
record_format MEDLINE/PubMed
spelling pubmed-92842492022-07-27 Genome stability of the vaccine strain VACΔ6 Maksyutov, R.A. Yakubitskiy, S.N. Kolosova, I.V. Tregubchak, T.V. Shvalov, A.N. Gavrilova, E.V. Shchelkunov, S.N. Vavilovskii Zhurnal Genet Selektsii Original Article Due to cessation of mass smallpox vaccination in 1980, the collective immunity of humans against orthopoxvirus infections has virtually been lost. Therefore, the risk of spreading zoonotic human orthopoxvirus infections caused by monkeypox and cowpox viruses has increased in the world. First-generation smallpox vaccines based on Vaccinia virus (VAC) are reactogenic and therefore not suitable for mass vaccination under current conditions. This necessitates the development of modern safe live vaccines based on VAC using genetic engineering. We created the VACΔ6 strain by transient dominant selection. In the VACΔ6 genome, f ive virulence genes were intentionally deleted, and one gene was inactivated by inserting a synthetic DNA fragment. The virus was passaged 71 times in CV-1 cells to obtain the VACΔ6 strain from the VAC LIVP clonal variant. Such a long passage history might have led to additional off-target mutations in VACΔ6 compared to the original LIVP variant. To prevent this, we performed a genome-wide sequencing of VAC LIVP, VACΔ6, and f ive intermediate viral strains to assess possible off-target mutations. A comparative analysis of complete viral genomes showed that, in addition to target mutations, only two nucleotide substitutions occurred spontaneously when obtaining VACΔ4 from the VACΔ3 strain; the mutations persisting in the VACΔ5 and VACΔ6 genomes. Both nucleotide substitutions are located in intergenic regions (positions 1431 and 189738 relative to LIVP), which indicates an extremely rare occurrence of off-target mutations when using transient dominant selection to obtain recombinant VAC variants with multiple insertions/deletions. To assess the genome stability of the resulting attenuated vaccine strain, 15 consecutive cycles of cultivation of the industrial VACΔ6 strain were performed in 4647 cells certif ied for vaccine production in accordance with the “Guidelines for Clinical Trials of Medicinal Products”. PCR and sequencing analysis of six DNA fragments corresponding to the regions of disrupted genes in VACΔ6 showed that all viral DNA sequences remained unchanged after 15 passages in 4647 cells. The Federal Research Center Institute of Cytology and Genetics of Siberian Branch of the Russian Academy of Sciences 2022-07 /pmc/articles/PMC9284249/ /pubmed/35903306 http://dx.doi.org/10.18699/VJGB-22-48 Text en Copyright © AUTHORS https://creativecommons.org/licenses/by/2.5/This work is licensed under a Creative Commons Attribution 4.0 License
spellingShingle Original Article
Maksyutov, R.A.
Yakubitskiy, S.N.
Kolosova, I.V.
Tregubchak, T.V.
Shvalov, A.N.
Gavrilova, E.V.
Shchelkunov, S.N.
Genome stability of the vaccine strain VACΔ6
title Genome stability of the vaccine strain VACΔ6
title_full Genome stability of the vaccine strain VACΔ6
title_fullStr Genome stability of the vaccine strain VACΔ6
title_full_unstemmed Genome stability of the vaccine strain VACΔ6
title_short Genome stability of the vaccine strain VACΔ6
title_sort genome stability of the vaccine strain vacδ6
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9284249/
https://www.ncbi.nlm.nih.gov/pubmed/35903306
http://dx.doi.org/10.18699/VJGB-22-48
work_keys_str_mv AT maksyutovra genomestabilityofthevaccinestrainvacd6
AT yakubitskiysn genomestabilityofthevaccinestrainvacd6
AT kolosovaiv genomestabilityofthevaccinestrainvacd6
AT tregubchaktv genomestabilityofthevaccinestrainvacd6
AT shvalovan genomestabilityofthevaccinestrainvacd6
AT gavrilovaev genomestabilityofthevaccinestrainvacd6
AT shchelkunovsn genomestabilityofthevaccinestrainvacd6